Mumbai, April 2 -- Gross advances increased 13.6% to Rs 6.68 lakh crore as of 31 March 2026 as against Rs 5.88 lakh crore as of 31 March 2025. The bank's total business grew 13.1% to Rs 14.98 lakh cro... Read More
Mumbai, April 2 -- India's defence exports have reached an all-time high of Rs 38,424 crore in the financial year 2025-26, registering a significant increase of Rs 14,802 crore (62.66%) compared to Rs... Read More
India, April 2 -- Royal Enfield has closed the bookings for the Sundowner Edition of the Meteor 350. The motorcycle has been taken off from Royal Enfield's website. The Sundowner Edition was a limited... Read More
Afghanistan, April 2 -- U.S. President Donald Trump has warned that Washington will strike Iran "extremely hard" over the next two to three weeks, signaling a possible new escalation in the ongoing co... Read More
Dhaka, April 2 -- In today's mobile-first environment, smartphones have become the primary way many people watch TV series, and Xiaomi phones, known for their strong performance and affordability, are... Read More
భారతదేశం, ఏప్రిల్ 2 -- భారత స్టాక్ మార్కెట్లు గురువారం ట్రేడింగ్లో కుప్పకూలాయి. ఏప్రిల్ 2వ తేదీ ఉదయం నుంచే నష్టాలతో ప్రారంభమైన సూచీలు, సమయం గడిచేకొద్దీ తీవ్ర పతనానికి గురయ్యాయి. బాంబే స్టాక్ ఎక్స్ఛేం... Read More
Singapore, April 2 -- The Health Sciences Authority received information related to the study titled 'ROSETTA CRC-203: A Blinded, Randomized Phase 2/3 Study of Pumitamig in Combination with Chemothera... Read More
Singapore, April 2 -- The Health Sciences Authority received information related to the study titled 'A Phase 3, Multicenter, Randomized, Double-Blinded, Placebo-Controlled Study to Evaluate the Safet... Read More
Singapore, April 2 -- The Health Sciences Authority received information related to the study titled 'A Phase III, Randomized, Open-Label, Multicenter, Global Study of Puxitatug Samrotecan (AZD8205) M... Read More
Singapore, April 2 -- The Health Sciences Authority received information related to the study titled 'DAREON®-Lung 1: A Phase III multi-center, open-label, randomised trial of intravenous obrixtamig i... Read More